Fingerprint
Dive into the research topics of 'ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease
Kyungho Kim, Jing Li, Andrew Barazia, Alan Tseng, Seock Won Youn, Giovanni Abbadessa, Yi Yu, Brian Schwartz, Robert K. Andrews, Victor R. Gordeuk, Jaehyung Cho
- Bursky Center for Human Immunology & Immunotherapy Programs (CHiiPs)
- Roy and Diana Vagelos Division of Biology & Biomedical Sciences (DBBS)
- Institute of Clinical and Translational Sciences (ICTS)
- Siteman Cancer Center
- Division of Hematology
- DBBS - Molecular Cell Biology
- DBBS - Immunology
- DBBS - Biochemistry, Biophysics, and Structural Biology
- Intellectual and Developmental Disabilities Research Center (IDDRC)
- Hope Center for Neurological Disorders
Research output: Contribution to journal › Article › peer-review
25
Scopus
citations